• Publications
  • Influence
A role for glucagon-like peptide-1 in the central regulation of feeding
THE sequence of glucagon-like peptide-1 (7–36) amide (GLP-1) is completely conserved in all mammalian species studied, implying that it plays a critical physiological role1. We have shown that GLP-1Expand
  • 1,675
  • 90
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
BACKGROUND The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baselineExpand
  • 712
  • 46
  • PDF
Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome.
AIMS Obstructive sleep apnoea (OSA) is associated with increased cardiovascular morbidity and mortality. Although it was previously assumed that this was due to its relation with obesity, recent dataExpand
  • 751
  • 28
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
Canagliflozin is a sodium glucose co‐transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double‐blind, placebo‐controlled, Phase 3 study evaluatedExpand
  • 248
  • 24
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
BACKGROUND Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the associated weight gain in patients withExpand
  • 315
  • 22
  • PDF
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers
OBJECTIVE To determine whether dapagliflozin, which selectively inhibits renal glucose reabsorption, lowers hyperglycemia in patients with type 2 diabetes that is poorly controlled with high insulinExpand
  • 364
  • 21
  • PDF
Gut peptides and the regulation of appetite
There is a growing worldwide epidemic of obesity. Obese people have a higher incidence of type 2 diabetes and cardiovascular disease, and hence present increasing social, financial and healthExpand
  • 210
  • 17
A parametric analysis of olanzapine-induced weight gain in female rats
RationaleSome novel antipsychotics, including olanzapine, induce weight gain and metabolic abnormalities, which represent the major adverse effects of these drugs. However, the mechanism(s) involvedExpand
  • 119
  • 15
Food fails to suppress ghrelin levels in obese humans.
UNLABELLED Ghrelin is the first circulating hormone shown to stimulate feeding in humans following systemic administration. Food consumption decreases circulating ghrelin concentrations in leanExpand
  • 521
  • 14
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
BACKGROUND In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced theExpand
  • 151
  • 13